Ro 04-6790

Ro 04-6790 is a pharmacological compound that acts as a 5-HT6 receptor antagonist. It was developed by Hoffmann-La Roche, a Swiss multinational healthcare company. Ro 04-6790 is primarily used in scientific research to investigate the role of 5-HT6 receptors in the brain.

History

Ro 04-6790 was first synthesized by researchers at Hoffmann-La Roche in the late 20th century. The compound was developed as part of a broader effort to understand the role of various serotonin receptor subtypes in the brain and their potential as targets for therapeutic intervention.

Pharmacology

Ro 04-6790 is a potent and selective antagonist of the 5-HT6 receptor, a subtype of serotonin receptor. This receptor is primarily found in the central nervous system, particularly in regions of the brain associated with learning and memory. By blocking the action of serotonin at these receptors, Ro 04-6790 can modulate neuronal activity in these regions.

Research Applications

Ro 04-6790 has been used in a variety of preclinical studies to investigate the role of 5-HT6 receptors in the brain. These studies have suggested that 5-HT6 receptor antagonists like Ro 04-6790 may have potential therapeutic applications in conditions such as schizophrenia, Alzheimer's disease, and obesity.

Safety and Toxicity

As a research compound, Ro 04-6790 is not approved for use in humans. Therefore, information on its safety and toxicity is limited to preclinical studies. In these studies, Ro 04-6790 has generally been well-tolerated, with no significant adverse effects reported at doses that produce a pharmacological effect.

See Also

• 5-HT6 receptor
• Serotonin receptor
• Hoffmann-La Roche

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

• 
  Ro_04-6790